Handelsbanken Fonder AB Has $1.81 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Handelsbanken Fonder AB raised its position in Glaukos Co. (NYSE:GKOS - Free Report) by 25.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 18,400 shares of the medical instruments supplier's stock after acquiring an additional 3,700 shares during the period. Handelsbanken Fonder AB's holdings in Glaukos were worth $1,811,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. State of Wyoming lifted its position in shares of Glaukos by 2.3% during the 4th quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock valued at $487,000 after acquiring an additional 72 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock valued at $345,000 after buying an additional 73 shares during the period. Mutual of America Capital Management LLC boosted its position in Glaukos by 1.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock worth $1,252,000 after purchasing an additional 89 shares during the period. HighTower Advisors LLC boosted its position in Glaukos by 2.8% during the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after purchasing an additional 91 shares during the period. Finally, Stifel Financial Corp boosted its position in Glaukos by 2.6% during the 4th quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock worth $651,000 after purchasing an additional 111 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Needham & Company LLC cut their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Mizuho cut their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Wells Fargo & Company cut Glaukos from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $160.00 to $86.00 in a report on Thursday, May 1st. Stephens decreased their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley decreased their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Glaukos has an average rating of "Moderate Buy" and a consensus price target of $134.67.

Glaukos Trading Up 0.1%

Shares of Glaukos stock traded up $0.09 on Friday, hitting $97.69. 797,572 shares of the company's stock traded hands, compared to its average volume of 726,788. The firm's 50-day moving average price is $92.76 and its two-hundred day moving average price is $119.82. The stock has a market capitalization of $5.58 billion, a PE ratio of -34.04 and a beta of 0.80. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. During the same quarter in the previous year, the business earned ($0.70) EPS. The firm's revenue was up 24.6% on a year-over-year basis. On average, research analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.80% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.